Regeneron and astrazeneca to research, develop and commercialize new small molecule medicines for obesity

Tarrytown, n.y., july 27, 2021 /prnewswire/ -- regeneron pharmaceuticals, inc. (nasdaq: regn) and astrazeneca today announced that the companies have entered into a collaboration to research, develop and commercialize small molecule compounds directed against the gpr75 target with the potential to treat obesity and related co-morbidities.

REGN Ratings Summary

REGN Quant Ranking